GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (FRA:137) » Definitions » Common Stock

Aldeyra Therapeutics (FRA:137) Common Stock : €0.06 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aldeyra Therapeutics Common Stock?

Aldeyra Therapeutics's quarterly common stock declined from Jun. 2024 (€0.06 Mil) to Sep. 2024 (€0.05 Mil) but then increased from Sep. 2024 (€0.05 Mil) to Dec. 2024 (€0.06 Mil).

Aldeyra Therapeutics's annual common stock declined from Dec. 2022 (€0.06 Mil) to Dec. 2023 (€0.05 Mil) but then increased from Dec. 2023 (€0.05 Mil) to Dec. 2024 (€0.06 Mil).


Aldeyra Therapeutics Common Stock Historical Data

The historical data trend for Aldeyra Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Common Stock Chart

Aldeyra Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.05 0.06 0.05 0.06

Aldeyra Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.06 0.05 0.06

Aldeyra Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Aldeyra Therapeutics Business Description

Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Aldeyra Therapeutics Headlines

No Headlines